TCR-T Immunotherapy: The Challenges and Solutions
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
T cell receptor-engineered T cell (TCR-T) therapy is free from the limit of surface antigen expression of the target cells, which is a potential cellular immunotherapy for cancer treatment. Significant advances in the treatment of hematologic malignancies with cellular immunotherapy have aroused the interest of researchers in the treatment of solid tumors. Nevertheless, the overall efficacy of TCR-T cell immunotherapy in solid tumors was not significantly high when compared with hematological malignancies. In this article, we pay attention to the barriers of TCR-T cell immunotherapy for solid tumors, as well as the strategies affecting the efficacy of TCR-T cell immunotherapy. To provide some reference for researchers to better overcome the impact of TCR-T cell efficiency in solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
(2023) · doi:10.1126/science · Cited by 6,063
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“During the clearing of acute infection, a population of activated T cells differentiates into high-functioning memory T cells; whereas, during chronic infection or in the TME, sustaining the activation of T cells can result in a dysfunctional phenotype, which is characterized by poor effector functions and expression…”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“IL-21, a type of thymus-stimulating cytokine that can trigger new thymus formation in aged mice, has shown significant immune storage function and promotes peripheral T cell pool regeneration (69, 70).”
BackgroundThe Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“Autoimmune toxicity can occur after the administration of immune checkpoint inhibitors (12– 14) and the infusion of genetically engineered T cells (14, 23, 74).”
BackgroundInterleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 1×
“When stimulated by local inflammation, IL-6 can promote the production of acute phase proteins by acting on the liver (85).”
Background
Cited by
Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., et al. (2022) · Cancers · doi:10.3390/cancers14174160 · Cited by 197
“Unlike TIL therapy, T cell receptorengineered T cell (TCR-T) therapy modifies the TCRs on the surface of endogenous T cells to recognize tumor-specific neoantigens [124].”
BackgroundBenoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“PD-1 inhibits T cell activation by targeting the signaling of the TCR and CD28 ([9]), and thus, it would be interesting to evaluate the potential of the combination of anti-PD-1 and TCR-T cells therapy.”
BackgroundInfluentialAdvances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
“However, the use of ACT in CRC still faces several challenges ( Figure 4 ) (7,37,38,104,106,139) .”
Immunosuppression and phenotypic plasticity in an atlas of human hepatocholangiocarcinoma
Li, Y., Xun, Z., Long, J., Sun, H., Yang, X., Wang, Y., Wang, Y., Xue, J., Zhang, N., Zhang, J., et al. (2024) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-23-400 · Cited by 2
“Nevertheless, the consistent presence of cold immune phenotypes (70) with latent impacts on the determinants of the dual phenotype of H-ChC was distinguished.”
Self-citation
Metadata
- Authors
- Liu, Y., Yan, X., Zhang, F., Zhang, X., Tang, F., Han, Z., & Li, Y.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-25
- Volume
- 11
- Pages
- 794183-794183
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W4207055527
- Cited by
- 117
- References
- 32
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TCR-T Immunotherapy: The Challenges and Solutions. https://app.cochat.ai/papers/10.3389/fonc.2021.794183
- The paper
- Liu, Y., Yan, X., Zhang, F., Zhang, X., Tang, F., Han, Z., & Li, Y. (2022). TCR-T Immunotherapy: The Challenges and Solutions. Frontiers in Oncology. https://doi.org/10.3389/fonc.2021.794183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.